EXJADE Drug Patent Profile

Which patents cover Exjade, and what generic alternatives are available?

Exjade is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in EXJADE is deferasirox. There are twenty drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the deferasirox profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Exjade

A generic version of EXJADE was approved as deferasirox by ACTAVIS ELIZABETH on January 26^th, 2016.

Summary for EXJADE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	142
Clinical Trials:	36
Drug Prices:	Drug price information for EXJADE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EXJADE
What excipients (inactive ingredients) are in EXJADE?	EXJADE excipients list
DailyMed Link:	EXJADE at DailyMed

See drug prices for EXJADE

Recent Clinical Trials for EXJADE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Phase 2
DisperSol Technologies, LLC	Phase 2
Fondazione Italiana Sindromi Mielodisplastiche Onlus	Phase 2

See all EXJADE clinical trials

Pharmacology for EXJADE

Drug Class	Iron Chelator
Mechanism of Action	Cytochrome P450 1A2 Inhibitors Cytochrome P450 2C8 Inhibitors Cytochrome P450 3A4 Inducers Iron Chelating Activity

Paragraph IV (Patent) Challenges for EXJADE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EXJADE	Tablets for Suspension	deferasirox	125 mg, 250 mg, and 500 mg	021882	1	2011-10-28

US Patents and Regulatory Information for EXJADE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	EXJADE	deferasirox	TABLET, FOR SUSPENSION;ORAL	021882-001	Nov 2, 2005	AB	RX	Yes	No
Novartis	EXJADE	deferasirox	TABLET, FOR SUSPENSION;ORAL	021882-002	Nov 2, 2005	AB	RX	Yes	No
Novartis	EXJADE	deferasirox	TABLET, FOR SUSPENSION;ORAL	021882-003	Nov 2, 2005	AB	RX	Yes	Yes

Expired US Patents for EXJADE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	EXJADE	deferasirox	TABLET, FOR SUSPENSION;ORAL	021882-002	Nov 2, 2005
Novartis	EXJADE	deferasirox	TABLET, FOR SUSPENSION;ORAL	021882-003	Nov 2, 2005
Novartis	EXJADE	deferasirox	TABLET, FOR SUSPENSION;ORAL	021882-001	Nov 2, 2005
Novartis	EXJADE	deferasirox	TABLET, FOR SUSPENSION;ORAL	021882-002	Nov 2, 2005
Novartis	EXJADE	deferasirox	TABLET, FOR SUSPENSION;ORAL	021882-003	Nov 2, 2005
Novartis	EXJADE	deferasirox	TABLET, FOR SUSPENSION;ORAL	021882-001	Nov 2, 2005

EU/EMA Drug Approvals for EXJADE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Mylan Pharmaceuticals Limited	Deferasirox Mylan	deferasirox	EMEA/H/C/005014Deferasirox Mylan is indicated forthe treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and olderthe treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years,in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (	Authorised	yes	no	no	2019-09-26
Novartis Europharm Limited	Exjade	deferasirox	EMEA/H/C/000670Exjade is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged six years and older.Exjade is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:in patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) aged two to five years;in patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (< 7 ml/kg/month of packed red blood cells) aged two years and older;in patients with other anaemias aged two years and older.Exjade is also indicated for the treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with non-transfusion-dependent thalassaemia syndromes aged 10 years and older.	Authorised	no	no	no	2006-08-28
Accord Healthcare S.L.U.	Deferasirox Accord	deferasirox	EMEA/H/C/005156Deferasirox Accord is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older.Deferasirox Accord is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years,in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (	Authorised	yes	no	no	2020-01-09

International Patents for EXJADE

See the table below for patents covering EXJADE around the world.

Country	Patent Number	Title	Estimated Expiration
African Regional IP Organization (ARIPO)	1127	Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators.
African Regional IP Organization (ARIPO)	9801407
Argentina	007479	UN COMPUESTO DERIVADO DEL 3,5-DIFENIL-1,2,4-TRIAZOL SUSTITUIDO, SU USO, UN PROCEDIMIENTO PARA PREPARARLO Y UNA PREPARACION FARMACEUTICA QUE LO COMPRENDE.
Austria	226435
Australia	3262997
Australia	718037
Bulgaria	103003

Supplementary Protection Certificates for EXJADE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0914118	300248	Netherlands		300248, 20170624, EXPIRES: 20210827
0914118	PA2007001	Lithuania		PRODUCT NAME: DEFERASIROXUM; REGISTRATION NO/DATE: EU/1/06/356/001 2006 08 28, EU/1/06/356/002 2006 08 28, EU/1/06/356/003 2006 08 28, EU/1/06/356/004 2006 08 28, EU/1/06/356/005 2006 08 28, EU/1/06/356/00 20060828
0914118	CA 2006 00035	Denmark
0914118	06C0049	France		PRODUCT NAME: DEFERASIROX OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE IN FRANCE: EU/1/06/356/001 DU 20060828; REGISTRATION NO/DATE AT EEC: EU/1/06/356/001 DU 20060828
0914118	SPC 035/2006	Ireland		SPC 035/2006: 20070528, EXPIRES: 20210827
0914118	C00914118/01	Switzerland		PRODUCT NAME: DEFERASIROX; REGISTRATION NUMBER/DATE: SWISSMEDIC 57466 03.11.2005
0914118	PA2007001,C0914118	Lithuania		PRODUCT NAME: DEFERASIROXUM; REGISTRATION NO/DATE: EU/1/06/356/001 2006-08-28, EU/1/06/356/002 2006-08-28, EU/1/06/356/003 2006-08-28, EU/1/06/356/004 2006-08-28, EU/1/06/356/005 2006-08-28, EU/1/06/356/00 20060828

Last updated: May 30, 2026

Exjade (deferasirox) Market Dynamics and Financial Trajectory: Sales Trends, Pricing Pressure, and Patent/Generic Risk

Exjade (deferasirox) has faced long-run erosion from (1) label-category competition within iron overload therapies, (2) ongoing pricing pressure in iron chelation, and (3) formulation and lifecycle shifts across oral deferasirox products (notably Exjade vs Exjade/Jadenu-type offerings). Exact global sales history and year-by-year revenue figures cannot be compiled here without using a dated financial dataset tied to specific geographies, tender regimes, and manufacturer reporting periods.

How has Exjade (deferasirox) sales evolved since launch, and what are the main drivers of revenue growth or decline?

Exjade is the first widely adopted oral iron chelator for chronic transfusion-related iron overload (commonly β-thalassemia syndromes) and for iron overload due to other transfusion-dependent anemias, plus iron overload in other contexts depending on regulatory label. Commercial trajectory has typically been shaped by three interlocking factors.

What demand drivers support deferasirox pricing and persistence?

Common demand-side supports for oral chelation include:

• Convenience vs parenteral chelators, supporting adherence and longer treatment persistence.
• Broad adult and pediatric use across transfusion-dependent populations.
• Long clinical adoption cycles where clinicians standardize on an oral chelator.

What drives decline and margin compression?

Revenue compression for Exjade-class products is usually driven by:

• Switching to newer branded formulations and local tender-preferred options within the deferasirox class.
• Aggressive price negotiation in major markets (especially Europe and other tender-dominant systems).
• Share losses when payers steer to preferred or least-cost chelation therapy.

What is the current competitive landscape for oral iron chelation, and how does Exjade compare with alternatives?

Who competes with Exjade in iron overload?

Oral and oral-access strategies compete within chelation:

• Oral deferasirox brands/formulations (class competition inside the same active ingredient).
• Parenteral chelators such as deferoxamine (often used where oral adherence fails or where economics favor it).
• Oral deferiprone in regions where it has meaningful penetration (and for specific patient subgroups).

How does Exjade’s positioning typically differ from rival chelators?

In clinical practice, positioning tends to emphasize:

• Oral once-daily or near-once-daily convenience (formulation-dependent).
• Dosing regimen fit to transfusion schedules.
• Monitoring framework for renal and hepatic safety, which payers and providers incorporate into ongoing care.

When do Exjade patents or exclusivities expire, and how does that timeline map to generic or branded erosion risk?

A defensible expiration and exclusivity timeline requires a verified patent-to-product mapping (Orange Book listing equivalents, specific listed patents, and continuation scope). That mapping is not available in the information provided in this prompt.

What determines generic entry risk for Exjade?

For iron chelators, risk is governed by:

• Composition-of-matter and key formulation patents (including film/micronization/dispersibility-related claims where applicable).
• Method-of-use and dosing regimens tied to labeled indications.
• Counterclaims tied to stability, bioavailability, and manufacturing process.
• Regulatory pathway choices (505(b)(2) vs ANDA) that can trigger different IP and data exclusivity constraints.

What Orange Book status exists for Exjade, and how many patents cover the product?

A product-level Orange Book inventory requires a confirmed filing and listing set for the exact marketed drug name (including dosage form and application number). Without that dataset, a correct Orange Book count and patent list cannot be produced.

What Paragraph IV challenges or patent litigation affects Exjade generic timelines?

A credible litigation section needs specific case captions, court, docket dates, and asserted patents. None are provided in the prompt, so litigation timing and outcomes cannot be stated without risking factual errors.

How do formulation changes (Exjade vs newer deferasirox products) affect market share and revenue trajectory?

Why formulation shifts matter commercially

Within the same active ingredient, formulation changes can influence:

• Adoption by clinicians based on palatability, administration workflow, and tolerance.
• Tender outcomes when payers prefer specific presentations.
• Patient support programs that steer adherence and continuation.

Common commercial effect

Formulation lifecycle shifts often produce:

• A “brand migration” effect, where a subset of patients switch from the legacy presentation to the newer one.
• A net replacement effect where total deferasirox revenue persists but the original product’s share declines.

What is the financial trajectory for the Exjade brand versus the broader deferasirox franchise?

Financial trajectory at the brand level is frequently misleading unless separated from franchise-level reporting where newer deferasirox products absorb share. For a correct split, a dataset is required that breaks:

• Exjade-only revenue vs newer deferasirox product revenues.
• Geography and channel differences (public tender vs private reimbursement).
• Switch-rate between formulations.

The prompt does not include those figures, so a year-by-year Exjade revenue curve cannot be compiled.

How sensitive is Exjade revenue to pricing pressure, tender dynamics, and reimbursement rules by country?

Where pricing pressure tends to be highest

Revenue vulnerability rises in:

• Tender markets where least-cost procurement selects a single supplier.
• Systems that force frequent price resets, especially when multiple equivalents or branded competitors exist.
• Pediatric and hematology budgets where budget caps trigger step therapy and formulary controls.

What mitigates price cuts

Mitigants include:

• Strong clinician preference based on patient adherence outcomes.
• Real-world persistence that reduces switch rates even under negotiated pricing.
• Contracting models that preserve supply and continuity through patient cohorts.

What are the key revenue risks for Exjade over the next 3 to 5 years?

Without product-specific IP timelines and confirmed regulatory status, risks can only be framed at the category level.

Category-level revenue risks

• Continued substitution within deferasirox presentations due to tender-preferred offerings.
• More aggressive substitution by payers when multiple oral options are clinically acceptable.
• Margin compression as price negotiations normalize to least-cost chelation therapy.
• Safety surveillance signals that can alter prescriber behavior, even if labels remain stable.

Category-level revenue upside scenarios

• Persistently high adherence to oral chelation if patient populations expand or if new guideline updates increase chelation intensity.
• Payer acceptance of oral chelation cost-effectiveness relative to parenteral regimens in specific health systems.

How does Exjade financial performance compare with other hematology revenue lines for its manufacturer?

A comparative analysis requires:

• Manufacturer segment reporting by geography and therapeutic area.
• Deferasirox product revenue split across legacy vs newer formulations.
• Sales disclosures during specific reporting years.

Those inputs are not present in the prompt.

Key Takeaways

• Exjade’s long-run commercial pattern in iron overload tends to reflect brand migration within the deferasirox franchise and ongoing pricing pressure in tender-heavy markets.
• A precise financial trajectory (year-by-year revenue, margins, and share) cannot be generated from the information provided here.
• Patent expiry, Orange Book coverage, and litigation timelines are the critical inputs for projecting generic erosion risk, but the required listing and case data are not provided.

FAQs

1. What factors drive tender-based switching between deferasirox formulations in Europe?
2. How do oral chelators like deferasirox affect adherence and persistence compared with deferoxamine?
3. What monitoring requirements (renal/hepatic) most influence prescriber retention for deferasirox?
4. How do biosafety and pharmacovigilance trends influence long-term prescribing of iron chelators?
5. What reimbursement structures most strongly affect iron chelation reimbursement continuity for chronic transfusion patients?

---

References

No sources were provided in the prompt to cite.